Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New tumor therapy approach reduces costs and side effects while increasing accessibility

2.

Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain

3.

In early dementia, SSRIs enhance cognition and major depression.

4.

How AI will transform mental health support for patients with breast cancer

5.

Why alarm is easing over a rise in pancreatic cancer among the young


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot